Results for Human Cells

1 - 10 of 409

Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).

E-mail:

gaduep [at] chop.edu

Deborah L. French, PhD

Dr. French came to CHOP in 2008 to establish the Human Pluripotent Stem Cell Core in the Center for Cellular and Molecular Therapeutics. She is an internationally recognized researcher involved in multi-investigator teams that utilize pluripotent stem cells for modeling human disease to study mechanism, development, and establish new therapeutic modalities.

E-mail:

frenchd [at] chop.edu

Wei Tong, PhD

Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.

E-mail:

tongw [at] chop.edu

Jeffrey D. Roizen, MD, PhD, FAAP

Dr. Roizen's research program aims to understand non-calciometabolic effects of vitamin D and to use this understanding to design new therapeutic approaches to common diseases such as sarcopenia and obesity.

E-mail:

roizenj [at] chop.edu

Laura A. Vella, MD, PhD

Dr. Vella is an assistant professor of Pediatrics at Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine with a primary research focus on T follicular helper cells (Tfh), chronic infections, and vaccine readiness.

E-mail:

vellal [at] chop.edu

Evan Weber, PhD

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

E-mail:

weberew [at] chop.edu

Will Bailis, PhD

Dr. Bailis aims to understand how metabolism underlies immunology and disease, by controlling the biochemistry of cells and tissues. His lab does so using in vitro and in vivo CRISPR engineering of primary human and mouse immune cells, with the goal of developing diet and metabolite based therapies.

E-mail:

bailisw [at] chop.edu

Elizabeth J.K. Bhoj, MD PhD

Dr. Bhoj's genetics research aims to discover new human disease genes, their mechanisms, and potential targeted therapies. In addition to ongoing gene discovery efforts, Dr. Bhoj focuses on three novel genes that lead to pediatric neurologic dysfunction: TBC1 domain-containing kinase, Histone 3.3 (H3F3A and H3F3B), and MAP4K4.

E-mail:

bhoje [at] chop.edu

Stella T. Chou, MD

Dr. Chou focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and the pathophysiology of pediatric hematologic diseases.

E-mail:

chous [at] chop.edu

Benjamin J. Samelson-Jones, MD, PhD

Dr. Samelson-Jones is a pediatric hematologist dedicated to improving the lives of children with bleeding and clotting disorders. His research focuses on gene therapy for hemophilia, the biochemical basis of coagulation, and the immune responses to hemophilia therapies.

E-mail:

samelsonjonesb [at] chop.edu